AXT (AXTI) Q1 2026 earnings review
Margins Surge and War Chest Grows, but Geopolitics Keep the Brakes On
AXT delivered a robust $26.9M in Q1 revenue, beating the $26M floor guidance provided last quarter. The real story is the operational recovery: Non-GAAP gross margins accelerated dramatically to 29.9%, a complete reversal from the negative 6.1% seen a year ago. Management capitalized on the AI-driven demand narrative by completing an eye-popping $632.5M capital raise in April to aggressively scale Indium Phosphide (InP) capacity. Despite this momentum, the company remains trapped in unprofitability (Non-GAAP net loss of $0.6M), heavily gated by China's opaque export permit process.
🐂 Bull Case
Gross margins reached 29.9%, proving that the manufacturing yield issues that crippled the company in early 2025 have been fully resolved.
With a newly secured $632.5M in capital, AXT is heavily armed to double its InP capacity and fund 6-inch wafer R&D to satisfy unprecedented AI data center demand.
🐻 Bear Case
Revenue remains entirely at the mercy of China's Ministry of Commerce. Demand means nothing if export permits are delayed or denied.
Inventory surged 10% sequentially to $90.2M. While management cites manufacturing ahead of demand, it highlights severe working capital drag caused by permit bottlenecks.
⚖️ Verdict: ⚪
Neutral. The margin recovery is highly impressive and the balance sheet is now fortress-like. However, the unpredictability of Chinese export controls makes near-term forecasting impossible, locking the stock in a geopolitical holding pattern.
Key Themes
Eye-Popping Capital Raise Signals Aggressive Scaling
In a massive structural shift, AXT completed a $632.5M capital raise in April 2026. This dwarfs their Q1 ending liquidity of $123M and historic CapEx needs. The funds are explicitly earmarked for Tongmei’s InP capacity expansion and R&D for new products. This level of capital injection fundamentally changes AXT's balance sheet and underscores the sheer scale of the AI infrastructure opportunity management is targeting.
AI Data Center Upgrades Driving InP Demand
The transition to higher-speed optical interconnects in AI data centers continues to be the primary engine for AXT. Indium phosphide substrates are critical ingredients for these optical data transmissions, keeping AXT's structural demand at record levels.
Gross Margin Trajectory Reversing Upward
Accelerating. Non-GAAP gross margin improved sequentially from 21.5% to 29.9%. This essentially achieves the company's long-stated 30% target and completely erases the catastrophic -6.1% print from exactly one year ago. Better factory utilization and resolved yield issues are finally flowing to the bottom line.
Transitioning to 6-Inch Indium Phosphide
A key technology innovation highlighted this quarter is the accelerated R&D investment into 6-inch InP substrates. Scaling wafer size is critical for improving yields for top-tier optical transceiver manufacturers and defending AXT's market share against emerging competitors.
Inventory Pile-Up Contradicts 'Scramble for Supply' Narrative
Despite management's previous claims of customers urgently scrambling for supply, inventory jumped sharply from $81.7M in 25Q4 to $90.2M in 26Q1. This metric explicitly contradicts the flawless demand narrative, revealing that AXT is stockpiling finished goods (WIP) that it physically cannot ship due to bureaucratic bottlenecks.
Macro Geopolitics: The MOFCOM Chokehold
Stable but highly restrictive. China's Ministry of Commerce export permit process remains the single largest operational risk. AXT is fundamentally capped not by what it can sell or produce, but by what the Chinese government allows it to export.
Bottom Line Remains in the Red
While the top line and gross margins are recovering, AXT still posted a GAAP net loss of $1.6M and a Non-GAAP net loss of $0.6M. Operating expenses remain elevated at $8.6M. True profitability requires higher volume throughput, which currently faces an administrative ceiling.
Other KPIs
Accelerating improvement. Reduced significantly from a $2.3M loss in 25Q4 and an $8.2M loss in 25Q1. EPS was a loss of $0.01, narrowly missing breakeven but easily beating the previously guided range of -$0.02 to -$0.04.
Stable. SG&A was $6.55M and R&D was $3.01M. The company has maintained steady expense control compared to the $9.03M reported a year ago, allowing the gross margin expansion to directly reduce the operating deficit.
Prior to the massive April capital raise, AXT ended March with $41.8M in cash, $16.1M in restricted cash, and $65.4M in short-term investments. Short-term loans crept up slightly to $68.9M.
Guidance
Stable. The company reiterated that its subsidiary's listing remains subject to review and approval by the CSRC. Management 'hopes to accomplish this goal in the coming months', unchanged from prior quarters.
Key Questions
Capital Raise Deployment
You completed a staggering $632.5M capital raise in April. What is the specific deployment timeline for these funds between 6-inch R&D and outright capacity expansion, and does this signal M&A ambitions?
Export Permit Visibility
Inventory rose another $8.5M this quarter. At what point does the lack of export permit velocity force you to slow down production to protect working capital?
Gross Margin Sustainability
You essentially hit 30% Non-GAAP gross margin in Q1. Is this the new structural floor assuming stable volume, or were there favorable one-time product mix elements?